[Results of some clinical-pharmacological studies on ambroxol (NA 872)].
In the beginning objects and problems of clinical pharmacology were outlined. Results from experimental studies in animals with the metabolite VIII of bromhexine (N-[trans-4-hydroxy-cyclohexyl]=[2-amino-3,5-dibromo-benzyl]-amine, Ambroxol (NA 842)) are described in order to contribute to the understanding of this substance's mode of action. Hence NA 872 is an expectorant which fully meets all requirements expected from this category of druggs -- increase in sputum amount, easement in breathing, reducing the viscosity, and depression of coughing. The dose-effect rate of the substance was tested in 54 adults and 32 children. The average dose of 45.0 mg/kg for adults was determined as sufficient for the majority of patients. In the following test in 124 patients on dose tolerance and efficacy, the substance proved to be tolerated extremely well, to cause no adverse side effects while achieving good effects particularly with regard to improvement of expectoration. There was no casual relationship between some occurring changes in laboratory data and the application of the substance.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D001964:Bromhexine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008875:Middle Aged; D013997:Time Factors
D005100:Expectorants; D001964:Bromhexine
Ergebnisse einiger klinisch-pharmakologischer Untersuchungen mit Ambroxol (NA 872)